Trial of Solanezumab in Preclinical Alzheimer’s Disease
Reisa A. Sperling(Harvard University), Paul Aisen(University of Southern California), Michael S. Rafii(University of Southern California), Michael Donohue(Alzheimer’s Disease Neuroimaging Initiative), Keith Johnson(Brigham and Women's Hospital), Colin L. Masters(Mental Health Research Institute), Gad A. Marshall, Rema Raman(University of Southern California), Takeshi Iwatsubo(National Center of Neurology and Psychiatry), Michele Mancini(Bank of Italy), Christopher H. van Dyck(Yale University), R. Yaari(Eli Lilly (United States)), Michael Case(Eli Lilly (United States)), John R. Sims(Eli Lilly (United States)), Karen C. Holdridge(Eli Lilly (United States))
Cited by 382
Related Papers
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
|Alzheimer s & Dementia|2018|10.4k
Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
|Alzheimer s & Dementia|2011|7.1k
Lecanemab in Early Alzheimer’s Disease
|New England Journal of Medicine|2022|5k
Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease
|New England Journal of Medicine|2012|3.8k
A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease
|Alzheimer s & Dementia|2014|3.1k